Serum osteocalcin levels are decreased in patients with type 2 diabetes mellitus and associated with bone and cardiovascular biomarkers

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: MON 776-795-Cardiometabolic Risk & Vascular Biology
Monday, June 17, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board MON-783
Damien Gruson*1, Anais Bothy1, Thibault Lepoutre2 and Michel Hermans3
1Cliniques Universitaires Saint Luc, Brussels, Belgium, 2cliniques universitaires saint luc, 3Cliniques Universitaires Saint Luc, Belgium
Background. Circulating biomarkers are increasingly used for risk stratification, in patients with type 2 diabetes mellitus (T2DM). The accumulating evidence suggests interactions between bone, phosphorus and energy metabolism in T2DM patients. Osteocalcin (OC), one of the osteoblast-specific proteins, has several hormonal features and is secreted in the general circulation from osteoblastic cells. Recent data have suggested that OC might act a hormone that regulates glucose metabolism and fat mass. The aim of our study was to determine the circulating levels of OC in T2DM patients and to assess its relationship with parathyroid hormone (PTH) 1-84 and Beta-crosslaps as well as with high sensitive troponin T (hsTnT) and N-terminal pro B-type natriuretic peptide (Nt-proBNP), some established biomarkers of cardiovascular risk.

Materials and methods: Two hundred forty patients with T2DM (mean age: 66 years, mean duration of diabetes 13,7 ± 8,9 years) were included in the study. Circulating levels of OC, PTH 1-84, Beta-crosslaps, Nt-proBNP and hsTnT were determined with the Cobas® e411 analyzer (Roche Diagnostics).

Results: OC levels were significantly lower in T2DM patients (mean: 12.9 ng/mL) than in healthy individuals (25 ng/mL). Mean circulating levels were 175 mg/dL for fasting glucose (range: 95 – 390), 7.7% for HbA1c (5.3 – 11.9), 0.190 ng/mL for Beta-crosslaps (0.044 – 0.632), 24.8 pg/mL for PTH 1-84 (5.6 – 83.5), 12.9 pg/mL for hsTnT (3.6 – 79.2) and 151 pg/mL for Nt-proBNP (5 – 832). In multiple regression analysis adjusted for age, duration of diabetes, body mass index and serum creatinin OC levels were negatively correlated to HbA1c (r = -0.198, P = 0·0143) and positively correlated to PTH 1-84 (r = 0.595, P = 0.02), Beta-crosslaps  (r = -0.781, P < 0.001) and Nt-proBNP (r = 0.310, P = 0.024). OC levels were not significantly related to hsTnT levels.

Conclusions: Our results suggest an independent association of OC levels with markers of bone turnover in patients with T2DM and with Nt-proBNP, a biomarker related to cardiovascular risk.

Nothing to Disclose: DG, AB, TL, MH

*Please take note of The Endocrine Society's News Embargo Policy at